ClinTec appoints Rick Farris as executive vice president of North American Operations
pharmafile | September 13, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | ClinTec, appointment
Clinical research organisation ClinTec has announced the expansion of its US management team with the selection of Rick Farris as its executive vice president of North American Operations.
Farris brings to the role almost 30 years of experience in the life sciences industry, formerly serving as vice president in project management for the Biopharma and Rare Diseases Unit at Novella Clinical, a Quintiles-owned company. In the position he provided client relationship management and project oversight for clinical trials in rare diseases, oncology, haematology, infectious disease, dermatitis, pain management, and gastroenterology.
Over the course of his career, Farris has also served as COO of CRO Health Decisions and has worked within the healthcare technology industry providing solutions for patient information management, electronic health records, clinical management, and financial management within the clinical environment.
CEO and founder of ClinTec International, Dr Rabinder Buttar remarked. “Rick will provide executive leadership to our teams and keep in close contact with our clients to ensure that as we continue to maintain our focus on high quality project delivery, remain highly responsive to client needs and provide a high level of customer service”.
Farris himself said of his appointment: “As ClinTec’s executive vice president of operations for North America, I am thrilled to be joining the organisation at a time of significant global growth, with the USA being a key market of strategic importance to our company. I look forward to working with ClinTec’s executive leadership as well as the USA leadership team to expand further our presence in North America by providing highly responsive and top quality research services, seamlessly integrated with the outputs from our teams across the globe. With so many trials struggling with enrollment, particularly in rare disease and oncology, ClinTec’s global footprint and permanent staff in 50 countries offers a unique opportunity for North American based companies needing to find patients wherever they are.”
Related Content
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …
